Kornimate/medical-research-clean huggingface dataset:
thrombectomy in st elevation myocardial infarction, an individual patient meta-analysis

Conditions: Myocardial Infarction; Acute Coronary Syndromes

Summary: during primary percutaneous coronary intervention, distal embolization of thrombus and impaired microvascular perfusion has been associated with an increased mortality. thrombectomy devices during primary percutaneous coronary intervention may prevent distal embolization by reducing thrombus burden and thus improve microvascular perfusion and reduce mortality.

an individual patient meta-analysis of large randomized controlled trials comparing manual thrombectomy versus percutaneous coronary intervention alone in patients with st elevation myocardial infarction will provide significantly more power to detect differences in mortality as well as important but rare events such as stroke and to assess benefits in pre-defined subgroups.

Eligibility criteria:
inclusion criteria: * randomized controlled trials comparing manual thrombectomy vs. percutaneous coronary intervention alone in patients with st elevation myocardial infarction published between january 1980 and april 2015. * large trials randomizing more than 1000 patients. * trials must have had at least 30 day follow up. exclusion criteria: -

Keywords: thrombectomy acute coronary syndromes percutaneous coronary intervention stemi
structural and functional left ventricular remodelling in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: the purpose of this study is to determine whether patients with obstructive sleep apnea have any changes in left ventricular function and structure after 06 months of continuous positive airway pressure treatment.

several studies have been suggesting that obstructive sleep apnea contributes to deterioration of left ventricular diastolic function. it may be associated to increased risk of cardiovascular events. we hypothesized that morphological and functional left ventricular changes might be reverted after treatment with continuous positive airway pressure.

Eligibility criteria:
inclusion criteria: * apnea-hypopnea index higher than 5 events per hour exclusion criteria: * body mass index higher than 40 kg/m2
clinical trial to preliminarily assess the safety and feasibility of sat-014, a software for alleviating symptoms of trauma and stress-related disorders

Conditions: Posttraumatic Stress Disorder

Summary: failure to adapt to stress leads to functional impairments in various areas, including social, occupational, educational, and other significant domains, necessitating therapeutic intervention. interventions through mobile app in the form of software can provide a new alternative for alleviating symptoms caused by psychological trauma by increasing accessibility to early intervention for trauma patients. this study aims to preliminarily assess the safety and feasibility of a psychological traum intervention by developing sat-014 to help patients with trauma and stress-related disorder continue effective treatment in a stable environment.


Eligibility criteria:
inclusion criteria: 1. adults (19 years and older) 2. have experienced clinically significant psychological trauma within the 6 months prior to screening visit 3. met the diagnostic criteria for post-traumatic stress disorder (ptsd) or adjustment disorder (ad) category as evaluated by mini (mini-international neuropsychiatric interview) 4. score between 17 and 38 points on the ies-r (impact of event scale-revised) 5. score of 4 or less on cgi (clinical global impression) 6. capable of complying the activity instructions provided the app exclusion criteria: 1. have been diagnosed with schizophrenia, bipolar disorder, and psychotic disorder 2. have been diagnosed with neurodevelopmental disorder, neurocognitive disorder, or organic mental disorder 3. severe depression (phq-9 score of 20 or greater) 4. comorbid with severe personality disorder 5. diagnosed with substance use disorder excluding nicotine and caffeine and with severe alcohol use disorder 6. have made a suicide attempt within 3 months and are judged to be at high risk for suicide by a psychiatrist 7. pregnant or lactating 8. currently participating in another clinical trial or have participated in another trial within 90 days from screening 9. others deemed unsuitable for participation in this clinical trial at the discretion of the investigator due to ethical concerns or potential impact on the trial outcome
cellular and molecular mechanisms governing bone marrow stem cells in gaucher disease

Conditions: Gaucher Disease

Summary: gaucher disease is an inherited autosomal recessive lysosomal storage disorder caused by the defective activity of the glucocerebrosidase, leading to accumulation of glucocerebroside particularly in cells of the macrophage lineage. clinical manifestations associate hematological, neurological and bone disorders.

gaucher disease is an inherited autosomal recessive lysosomal storage disorder caused by the defective activity of the glucocerebrosidase, leading to accumulation of glucocerebroside particularly in cells of the macrophage lineage. clinical manifestations associate hematological, neurological and bone disorders. in this project, the investigators aimed to study the cellular and molecular mechanisms governing the biology of various cell populations of the bone marrow and blood in these patients in order to define their potential role in the physiopathology of the disease. the main research topics the investigators plan will then be focused on characterization and functional analysis of hematopoietic stem cells, mesenchymal stem cells (with a special focus on osteogenic differentiation), macrophages and osteoclastic differentiation, b lymphocytes and plasma cells.

Eligibility criteria:
inclusion criteria: * age \> 18 years * gaucher disease * clinical examination written consent exclusion criteria: * pregnancy * hiv seropositive * contraindication to bone marrow sampling

Keywords: gaucher disease
echocardiography for rili prediction

Conditions: NSCLC

Summary: severe radiation-induced lung injury (rili) occurs in approximately 20% of the lung cancer patients, who are treated with curative chemoradiation. in this study the investigators want to evaluate the prognostic value of baseline cardiac function assessed with echocardiography for prediction of rili.

severe radiation-induced lung injury (rili) occurs in approximately 20% of the lung cancer patients, who are treated with curative chemoradiation (crt).this side-effect can heavily impact quality of life and is a dose-limiting factor for the treatment. identifying high risk patients before the start of the treatment would make it possible to adapt the treatment by choosing another radiation technique or proton therapy. however, despite the fact that many patient and treatment characteristics have been associated with rili, it is not possible to accurately predict the risk of rili for individual patients. recently, it has been shown that the radiation dose to the heart is a risk factor for lung toxicity in both animal and clinical studies. also, in a study, carried out jointly by carim and grow, it was found that patients with a previous diagnosis of cardiac disease had a significantly higher risk to develop rili after crt (p-value \<0.001), even with low or no radiation dose to the heart. it is unknown whether asymptomatic cardiac comorbidity is also related to development of rili. taking into account that approximately 30% of all lung cancer patients suffer from symptomatic cardiac comorbidity at the start of cancer treatment, there is an urgent need for research projects focusing on cardio-oncology. these projects will make it possible to unravel the complex relationship between heart, lungs, chemotherapy and radiation treatment. in the current project the investigators hypothesize that biomarkers based on echocardiography, which reflects cardiac function, are prognostic for development of radiation induced lung injury after chemoradiotherapy. in addition, the investigators will validate our previous finding that presence of cardiac comorbidity is associated with rili.

Eligibility criteria:
inclusion criteria: * clinical stage i-iii non small cell lung cancer, excluding malignant pleural/pericardial effusion * planned for curatively intended primary (chemo)radiotherapy, due to irresectable disease and/or medical inoperability * who performance status 0-2 * no history of prior chest radiotherapy * no uncontrolled infectious disease * no other active malignancy * no prior lung surgery (vats, wedge resection, segment resection, lobectomy) * willing and able to comply with the study prescriptions * 18 years or older * ability to give and having given written informed consent before patient registration exclusion criteria: * malignant pleural/pericardial effusion * history of prior chest radiotherapy * uncontrolled infectious disease * other active malignancy * prior lung surgery (vats, wedge resection, segment resection, lobectomy)

Keywords: echocardiography radiation-induced lung injury prognostic chemo radiotherapy non-small cell lung cancer nsclc
hematological dynamic scores for predicting survival and treatment response for advanced gastric cancer after neoadjuvant therapy

Conditions: Gastric Cancer

Summary: hmdls, based on hematological markers, could effectively distinguish the long-term efficacy of agc patients after nat. the predictive performance of nomogram-hmdls was better than yptnm stage, achieving better prognostic stratification and tumor treatment response prediction.

in this research, we incorporated a total of 320 patients from the union hospital of fujian medical university to form the training cohort (tc). additionally, we included 122 patients from four distinct medical centers to serve as the external validation cohort (evc). the hematological marker dynamic load (δhmdl) was determined using the following formula: δhmdl = (hmdl pre-surgery - hmdl pre-nat) / hmdl pre-nat, where hmdl represents the hematological marker levels before surgery and before the initiation of neoadjuvant therapy (nat), respectively. employing lasso regression analysis, we identified the most influential and statistically significant δhmdl indicators. these were then utilized to compute the hematological marker dynamic load score (hmdls), defined as: hmdls = σ(lasso coefficient \* δhmdl), where the summation encompasses the products of the lasso-estimated coefficients and the corresponding δhmdl values. further, leveraging the outcomes of a multivariate cox regression analysis, we integrated clinical parameters with the hmdls to formulate a predictive model, termed the nomogram-hmdls model. the efficacy of this model in terms of predictive accuracy, clinical utility, and calibration was meticulously assessed and confirmed through several metrics, including the concordance index (c-index), receiver operating characteristic (roc) curve analysis, decision curve analysis (dca), and calibration curves.

Eligibility criteria:
inclusion criteria: * (1) agc with clinical stage t2-4nxm0 (ct2-4nxm0) before nat, (2) no history of other malignant tumors, distant metastases or invasion of adjacent organs, and (3) patients who underwent radical gastrectomy after receiving nat. exclusion criteria: * (1) history of upper abdominal surgery (except for the laparoscopic cholecystectomy), (2) history of upper abdominal radiotherapy, (3) emergency surgery, or palliative surgery, (4) continuous use of medications such as anticoagulant, antiplatelet, and leukocyte-boosting drugs that significantly affect hematological markers during therapy, and (5) incomplete clinical and follow-up data.

Keywords: gastric cancer neoadjuvant chemotherapy inflammation oxidative stress treatment response risk stratification
immunological markers in adult patients with immune thrombocytopenic purpura

Conditions: Immune Thrombocytopenic Purpura; Splenectomy; Status

Summary: the aim of this study is to determine histological immunological parameters, sought on splenectomy pieces that may explain the failure or success of splenectomy in patients with itp who had a splenectomy to treat their itp(immune thrombocytopenic purpura).

immune thrombocytopenic purpura (itp) is a rare autoimmune thrombocytopenia whose incidence is 2 to 5 cases / 100,000 inhabitants / year. the potentially serious haemorrhagic risk is the major issue of management. a recent international consensus conference classifies pti according to the duration of thrombocytopenia: acute itp (\ 12 months) (rodeghiero 2009). in the acute or persistent phase, polyvalent immunoglobulins (ivig) and / or corticosteroids are proposed. in the chronic phase, splenectomy is a possible cure for 70% of patients. no predictor of treatment response is known. the pathophysiology of itp is multifactorial: platelet phagocytosis, mediated by autoantibody, macrophages of the reticuloendothelial system, and destruction in the spleen, genetic background and / or environmental factor favoring the role of certain lymphocyte subpopulations, cytotoxic or regulatory t, via their cytokine environment, abnormalities of thrombopoiesis. at present, no predictive factor of splenectomy success has been identified. the aim of this study is to determine histological immunological parameters, sought on splenectomy pieces that may explain the failure or success of splenectomy in patients with itp who had a splenectomy to treat their itp.

Eligibility criteria:
inclusion criteria: * the analyzed spleens belong to the collection of biological samples declared to the ministry by the laboratory of pathology of haut-lévêque hospital (dr parrens). exclusion criteria: * opposition of the patient.

Keywords: immunological parameters histological parameters
sequential expansion of comparative effectiveness of anticoagulants

Conditions: Atrial Fibrillation

Summary: this cohort study is the sequential expansion of the comparative effectiveness study of oral anticoagulants and plans to identify initiators of oral anticoagulants using electronic claims data from a commercial insurance database to quantify associations between anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in patients with non-valvular atrial fibrillation at risk for stroke.


Eligibility criteria:
inclusion criteria: * a recorded diagnosis of atrial fibrillation. * initiation of anticoagulant medication (dabigatran (or other new oral anticoagulants as they become available) or warfarin). * at least 18 years of age on the date of anticoagulant initiation. * congestive heart failure, hypertension, age \> 75, diabetes mellitus, prior stroke or transient ischemic attack, vascular disease, age 65-74, sex category (cha2ds2-vasc) score at least 1 exclusion criteria: * patients with missing or ambiguous age or sex information. * patients with evidence of valvular disease. * patients with less than 12 months enrolment preceding the date of anticoagulant initiation * patients with a dispensing of any oral anticoagulant during the 12 months preceding the date of anticoagulant initiation * patients with a nursing home stay during the 12 months preceding the date of anticoagulant initiation
atorvaststin and cardiotoxicity in acute myloid leukemia

Conditions: Leukemia; Hodgkin Disease

Summary: the research proposal focuses on evaluating the efficacy of atorvastatin in reducing cardiotoxicity caused by anthracycline chemotherapy in patients with hematologic malignancies, specifically acute myeloid leukemia (aml) and non-hodgkin lymphoma (nhl). the study will be conducted at assiut university hospitals and will include patients aged 18 or older receiving anthracycline-based treatments (3+7 regimen for aml and chop regimen for nhl). the background highlights that anthracyclines, a class of chemotherapeutic agents, can cause serious side effects, particularly cardiotoxicity. the research aims to investigate whether atorvastatin, a statin used to lower cholesterol, can mitigate this risk by improving cardiac function in patients undergoing chemotherapy. the study will be a randomized controlled trial with a sample size of 46 participants. it will assess left ventricular ejection fraction (lvef) as the primary outcome to determine the effect of atorvastatin on reducing cardiotoxicity. secondary outcomes include identifying high-risk patients and further understanding the impact of atorvastatin. the study also adheres to ethical guidelines, ensuring patient consent and confidentiality. data analysis will be performed using ibm spss, and results will be disseminated in scientific journals, with support from assiut medical school's grants office if funding is approved.


Eligibility criteria:
inclusion criteria: age \>18 years patient with hematologic malignany ( acute myeloid leukemia on 3,7 regimen or non-hodkin lymphoma on chop regimen) cardiac function with ef ≥60% exclusion criteria: cardiac dysfunction with ef \< 60% other hematologic malignancies pregnant women and breastfeeding patients refuse participate in research

Keywords: cardiotoxicity atrovastatin
the effects of treadmill versus agility training in parkinson's disease

Conditions: Exercise; Parkinson's Disease

Summary: aim: to determine the responsiveness of the imobility in response to intensive physical therapy exercise programs. (is it sensitive to change?) although exercise is thought to be the most effective intervention for balance and gait in pd (compared to dopaminergic medication or dbs surgery), the best exercise program for mobility in pd is unknown. the imobility will be used to quantify balance and gait performance before and after two pt-supervised, intensive, exercise programs, expected to improve balance and gait. the first program is a published treadmill training program and the second is the investigators new agility training program with sensorimotor progressions, targeted at specific impairments that underlie the abnormalities of balance and gait in pd (developed for the kinetics foundation). this pilot clinical trial will randomize 40 pd subjects into the two exercise programs at ohsu in preparation for a larger clinical trial to determine the most effective exercise for mobility disability in pd. the effects of exercise will be compared with no treatment during a 5-week delay prior to start of exercise. this trial will also determine the relative responsiveness (compared to traditional clinical scales) of the imobility for testing the hypothesis that intensive exercise can improve mobility in pd. we will use existing instruments (berg balance scale, best of dynamic balance, updrs, pdq-39, 5 times sit-to-stand time and the functional performance battery) to show there is a difference between the exercise groups. superior responsiveness of the imobility system will be determined by larger differences with exercise intervention with the imobility system than with traditional clinical measures of mobility in pd.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic pd exclusion criteria: * other neurological conditions, artificial joints
muscle strength loss in stroke individuals - control study

Conditions: Stroke Rehabilitation

Summary: abstract the muscle strength (ms) is necessary to overcome the resistance encountered during the activity. the present study aims to determine ms loss in stroke individuals (si). 33 si and 33 healthy individuals (hi) were included in this study. ms and handgrip force were assessed using a power track dynamometer and jamar hand dynamometer, respectively. the total ms of the hi was calculated by summing the muscle strength of the trunk, lower and upper extremities. in the si, the muscle strength of the trunk, unaffected upper and lower extremities were summed to calculate the total ms. to compare ms of unaffected sides (us) between groups, 27 si who was dominant and not affected on the right side and 33 hi who was dominant on the right side were used.


Eligibility criteria:
inclusion criteria: * for patient with stroke * between 30-65 ages * diagnosed with stroke chronic stroke patients (diagnosed with a stroke at least 6 months ago) for healthy individuals * 30-65 ages * healthy individuals exclusion criteria for patient with stroke * patient with an additional neurological disease to stroke * patients with orthopedic problems, * patients with mental and communication impairments * patients who scored more than 3 points for the modified rankin scale for healthy individuals; * who had active sporting life
myofunctional therapy in facial palsy

Conditions: Facial Paralysis

Summary: objective: quantify the benefits of myofunctional therapy associated to botulinum toxin injection in patients with long standing facial unilateral palsy.

twenty-five patients with long standing facial palsy were studied; all had been previously treated for facial reanimation. patients were randomly divided in two groups; group a did the myofunctional therapy sessions with the speech therapist before the botulinum toxin injection, while the participants of group b did the myofunctional therapy after it.

Eligibility criteria:
inclusion criteria: * facial paralysis with more than 2 years elapsed since the onset of symptoms * surgically treated for reanimation at least 12 months before * static and/or dynamic facial asymmetry causing aesthetic concern exclusion criteria: * spastic paralysis * serious systemic or neuromuscular diseases * cognition impairment * pregnant women

Keywords: facial paralysis asymmetry myofunctional therapy botulinum toxin facial evaluation
a study to evaluate the effect of cyclosporine, a p-glycoprotein, breast cancer resistance protein, and organic-anion-transporting polypeptide inhibitor, on pimodivir in healthy adults

Conditions: Healthy

Summary: the purpose of this study is to evaluate the effect of a single oral dose of cyclosporine on the pharmacokinetics of a single oral dose of pimodivir when coadministered to healthy adult participants under fasted conditions.


Eligibility criteria:
inclusion criteria: * willing and able to adhere to the prohibitions and restrictions specified in this protocol * a woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin \[beta-hcg\]) at screening and on day -1 of each treatment period * a woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the study and for a period of at least 30 days after the last study drug intake * a male participant must wear a condom when engaging in any activity that allows for passage of ejaculate to another person (male participants should also be advised of the benefit for a female partner to use a highly effective method of contraception as condom may break or leak) * a male participant must agree not to donate sperm for the purpose of reproduction during the study and for a minimum of 90 days after last study drug intake exclusion criteria: * history of or current clinically significant medical illness including (but not limited to) cardiac arrhythmias or other cardiac disease, hematologic disease, coagulation disorders (including any abnormal bleeding or blood dyscrasias), lipid abnormalities, significant pulmonary disease, including bronchospastic respiratory disease, diabetes mellitus, hepatic or renal insufficiency (creatinine clearance below 90 milliliter per minute at screening), gastrointestinal disease (such as significant diarrhea, gastric stasis, or constipation that in the investigator's opinion could influence drug absorption or bioavailability), thyroid disease, neurologic or psychiatric disease, infection, or any other illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results * history of clinically significant skin disease such as, but not limited to, dermatitis, eczema, drug rash, psoriasis, food allergy, or urticaria * known allergies, hypersensitivity, or intolerance to pimodivir and/or cyclosporine or their excipients * history of clinically significant drug allergy such as, but not limited to, sulfonamides and penicillins, or drug allergy diagnosed in previous studies with experimental drugs